Session 8 - CROI 2009

Session 8 Oral Abstracts
Prevention and Treatment of Serious OIs and Malignancies
Monday, 10 am-12:30 pm
Room: Room 517a

10:00 am 29	Risk of AIDS Non-Hodgkin's Lymphoma Is Strongly Predicted by Elevated Levels of Circulating Immunoglobulin-free Light Chains O Landgren¹, J Goedert¹, C Rabkin¹, W Wilson¹, K Dunleavy¹, R Kyle², J Katzmann², V Rajkumar², and Eric Engels*¹ ¹NCI, NIH, Bethesda, MD, US and ²Mayo Clinic, Rochester, MN, US
10:15 am 30	Infection-related Non-AIDS-defining Cancer Risk in HIV-infected and -uninfected Persons Michael Silverberg*¹, W Leyden¹, C Chao², L Xu², B Tang², M Horberg¹, D Klein³, W Towner⁴, and D Abrams⁵ ¹Kaiser Permanente, Oakland, CA, US; ²Kaiser Permanente, Pasadena, CA, US; ³Kaiser Permanente, Hayward Med Ctr, CA, US; ⁴Kaiser Permanente, Los Angeles Med Ctr, US; and ⁵San Francisco Gen Hosp, Univ of California, San Francisco, US
10:30 am 31	Kaposi’s Sarcoma-associated Immune Reconstitution Inflammatory Syndrome in Africa: Initial Findings from a Prospective Evaluation Jeffrey Martin*¹, M Laker², D Clutter¹, A Kambugu², J Orem³, D Janka¹, J Bennett¹, S Deeks¹, T Maurer¹, and E Mbidde⁴ ¹Univ of California, San Francisco, US; ²Infectious Disease Inst, Kampala, Uganda; ³Uganda Cancer Inst, Kampala; and ⁴Uganda Virus Res Inst, Entebbe
10:45 am 32	Successful Primary Prevention of Cryptococcal Disease Using Fluconazole Prophylaxis in HIV-infected Ugandan Adults Rosalind Parkes-Ratanshi*^1,2,3, A Kamali¹, K Wakeham¹, J Levin¹, C Nabiryo Lwanga⁴, N Kenya-Mugisha⁵, A Coutinho⁶, J Whitworth⁷, H Grosskurth¹, and D Lalloo² ¹Med Res Council, Uganda Virus Res Inst, Entebbe; ²Liverpool Sch of Tropical Med, UK; ³Imperial Coll, Univ of London, UK; ⁴The AIDS Support Org, Kampala, Uganda; ⁵Ministry of Hlth, Uganda; ⁶Infectious Disease Inst, Kampala, Uganda; and ⁷Wellcome Trust, London, UK
11:00 am 33	HIV-infected Ugandans on HAART with CD4 Counts >200 Cells/mm³ Who Discontinue Cotrimoxazole Have Increased Risk of Malaria and Diarrhea James Campbell*¹, D Moore¹, R Degerman¹, F Kaharuza¹, W Were¹, E Muramuzi¹, J Mermin^1,2, and J Tappero¹ ¹CDC, Atlanta, GA, US and ²CDC Kenya, Nairobi
11:15 am 34	Randomized Placebo-controlled Trial of Prednisone for the TB Immune Reconstitution Inflammatory Syndrome Graeme Meintjes*^1,2, R Wilkinson^1,2,3,4, C Morroni¹, D Pepper^1,2, K Rebe^1,2, M Rangaka¹, T Oni¹, and G Maartens¹ ¹Univ of Cape Town, South Africa; ²GF Jooste Hosp, Cape Town, South Africa; ³Natl Inst for Med Res, London, UK; and ⁴Imperial Coll London, UK
11:30 am 35	Once-daily Nevirapine vs Efavirenz in the Treatment of HIV-infected Patients with TB: A Randomized Clinical Trial Soumya Swaminathan*, C Padmapriyadarsini, P Venkatesan, G Narendran, R Kumar, S Iliayas, D Pooranaganga, M Dilip, R Sakthivel, and R Ramachandran TB Res Ctr, Chennai, India
11:45 am 36a	Initiating ART during TB Treatment Significantly Increases Survival: Results of a Randomized Controlled Clinical Trial in TB/HIV-co-infected Patients in South Africa Salim Abdool Karim*^1,2,3, K Naidoo¹, A Grobler¹, N Padayatchi^1,2, G Nair¹, S Bamber¹, J Pienaar¹, G Friedland⁴, W El-Sadr³, and Q Abdool Karim^1,2,3 ¹Ctr for AIDS Prgm of Res, Durban, South Africa; ²Univ of KwaZulu-Natal, Durban, South Africa; ³Columbia Univ, New York, NY, US; and ⁴Yale Univ, New Haven, CT, US
12:00 pm 36bLB	Novel Regimens for Treating Latent TB in HIV-infected Adults in South Africa: A Randomized Clinical Trial Neil Martinson*¹, G Barnes², R Msandiwa¹, L Moulton², G Gray¹, J McIntyre¹, H Hausler³, M Ram², and R Chaisson² ¹Univ of the Witwatersrand, Johannesburg, South Africa; ²Johns Hopkins Univ, Baltimore, MD, US; and ³TB Care Assn, Cape Town, South Africa
12:15 pm 36cLB	Early vs Delayed ART in the Treatment of Cryptococcal Meningitis in Africa Azure Makadzange*^1,2, C Ndhlovu², K Takarinda², M Reid², M Kurangwa², V Chikwasha², and J Hakim² ¹Univ of Washington, Seattle, US and ²Univ of Zimbabwe, Harare